vs
CSW INDUSTRIALS, INC.（CSW）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是Esperion Therapeutics, Inc.的1.4倍（$233.0M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 20.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 5.1%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CSW vs ESPR — 直观对比
营收规模更大
CSW
是对方的1.4倍
$168.4M
营收增速更快
ESPR
高出123.4%
20.3%
两年增速更快
ESPR
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $168.4M |
| 净利润 | $10.3M | — |
| 毛利率 | 39.7% | — |
| 营业利润率 | 7.4% | 50.6% |
| 净利率 | 4.4% | — |
| 营收同比 | 20.3% | 143.7% |
| 净利润同比 | -61.9% | — |
| 每股收益（稀释后） | $0.62 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWESPR
| Q4 25 | $233.0M | $168.4M | ||
| Q3 25 | $277.0M | $87.3M | ||
| Q2 25 | $263.6M | $82.4M | ||
| Q1 25 | $230.5M | $65.0M | ||
| Q4 24 | $193.6M | $69.1M | ||
| Q3 24 | $227.9M | $51.6M | ||
| Q2 24 | $226.2M | $73.8M | ||
| Q1 24 | $210.9M | $137.7M |
净利润CSWESPR
| Q4 25 | $10.3M | — | ||
| Q3 25 | $40.7M | $-31.3M | ||
| Q2 25 | $40.9M | $-12.7M | ||
| Q1 25 | $35.1M | $-40.5M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $36.1M | $-29.5M | ||
| Q2 24 | $38.6M | $-61.9M | ||
| Q1 24 | $31.8M | $61.0M |
毛利率CSWESPR
| Q4 25 | 39.7% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 43.8% | — | ||
| Q1 25 | 44.2% | — | ||
| Q4 24 | 41.4% | — | ||
| Q3 24 | 45.6% | — | ||
| Q2 24 | 47.5% | — | ||
| Q1 24 | 44.4% | — |
营业利润率CSWESPR
| Q4 25 | 7.4% | 50.6% | ||
| Q3 25 | 20.5% | -11.4% | ||
| Q2 25 | 20.8% | 8.6% | ||
| Q1 25 | 19.5% | -34.0% | ||
| Q4 24 | 15.3% | -6.4% | ||
| Q3 24 | 22.6% | -31.0% | ||
| Q2 24 | 24.3% | 3.5% | ||
| Q1 24 | 21.0% | 52.5% |
净利率CSWESPR
| Q4 25 | 4.4% | — | ||
| Q3 25 | 14.7% | -35.9% | ||
| Q2 25 | 15.5% | -15.4% | ||
| Q1 25 | 15.2% | -62.2% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 15.8% | -57.2% | ||
| Q2 24 | 17.1% | -83.9% | ||
| Q1 24 | 15.1% | 44.3% |
每股收益（稀释后）CSWESPR
| Q4 25 | $0.62 | $0.32 | ||
| Q3 25 | $2.41 | $-0.16 | ||
| Q2 25 | $2.43 | $-0.06 | ||
| Q1 25 | $2.05 | $-0.21 | ||
| Q4 24 | $1.60 | $-0.14 | ||
| Q3 24 | $2.26 | $-0.15 | ||
| Q2 24 | $2.47 | $-0.33 | ||
| Q1 24 | $2.03 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $-302.0M |
| 总资产 | $2.3B | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSWESPR
| Q4 25 | $40.2M | $167.9M | ||
| Q3 25 | $31.5M | $92.4M | ||
| Q2 25 | $38.0M | $86.1M | ||
| Q1 25 | $225.8M | $114.6M | ||
| Q4 24 | $213.8M | $144.8M | ||
| Q3 24 | $273.2M | $144.7M | ||
| Q2 24 | $18.9M | $189.3M | ||
| Q1 24 | $22.2M | $226.6M |
总债务CSWESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
股东权益CSWESPR
| Q4 25 | $1.1B | $-302.0M | ||
| Q3 25 | $1.1B | $-451.4M | ||
| Q2 25 | $1.1B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.0B | $-388.7M | ||
| Q3 24 | $1.0B | $-370.2M | ||
| Q2 24 | $650.2M | $-344.2M | ||
| Q1 24 | $615.7M | $-294.3M |
总资产CSWESPR
| Q4 25 | $2.3B | $465.9M | ||
| Q3 25 | $1.5B | $364.0M | ||
| Q2 25 | $1.5B | $347.1M | ||
| Q1 25 | $1.4B | $324.0M | ||
| Q4 24 | $1.4B | $343.8M | ||
| Q3 24 | $1.4B | $314.1M | ||
| Q2 24 | $1.1B | $352.3M | ||
| Q1 24 | $1.0B | $373.1M |
负债/权益比CSWESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | — |
| 自由现金流率自由现金流/营收 | 9.8% | — |
| 资本支出强度资本支出/营收 | 2.6% | 0.0% |
| 现金转化率经营现金流/净利润 | 2.81× | — |
| 过去12个月自由现金流最近4个季度 | $162.0M | — |
8季度趋势，按日历期对齐
经营现金流CSWESPR
| Q4 25 | $28.9M | $45.2M | ||
| Q3 25 | $61.8M | $-4.3M | ||
| Q2 25 | $60.6M | $-31.4M | ||
| Q1 25 | $27.3M | $-22.6M | ||
| Q4 24 | $11.6M | $-35.0M | ||
| Q3 24 | $66.8M | $-35.3M | ||
| Q2 24 | $62.7M | $-7.2M | ||
| Q1 24 | $22.4M | $53.8M |
自由现金流CSWESPR
| Q4 25 | $22.7M | — | ||
| Q3 25 | $58.7M | — | ||
| Q2 25 | $57.7M | — | ||
| Q1 25 | $22.8M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $61.3M | $-35.5M | ||
| Q2 24 | $59.6M | $-7.3M | ||
| Q1 24 | $17.5M | $53.8M |
自由现金流率CSWESPR
| Q4 25 | 9.8% | — | ||
| Q3 25 | 21.2% | — | ||
| Q2 25 | 21.9% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 26.9% | -68.7% | ||
| Q2 24 | 26.3% | -9.9% | ||
| Q1 24 | 8.3% | 39.0% |
资本支出强度CSWESPR
| Q4 25 | 2.6% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 2.0% | 0.0% | ||
| Q4 24 | 1.6% | 0.0% | ||
| Q3 24 | 2.4% | 0.3% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 2.3% | 0.1% |
现金转化率CSWESPR
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
